Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-09-02
1994-11-22
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
053669800
ABSTRACT:
This invention discloses a method for treating human patients suffering from dermatitis, particularly severe dermatitis which does not respond adequately to non-prescription drugs. Such patients are treated using dextromethorphan (DM), an antitussive agent normally used in cough syrup. If the patient is a so-called "extensive metabolizer," an antioxidant drug (such as quinidine) can be coadministered to inhibit the DM-degrading activity of debrisoquin hydroxylase, an enzyme that will rapidly convert DM into its metabolite, dextrorphan. This treatment has been shown to be highly effective in treating severe dermatitis, and in most patients this drug combination causes no significant adverse side effects.
REFERENCES:
patent: 5166207 (1992-11-01), Smith
patent: 5206248 (1993-04-01), Smith
Koppel, C., et al, "Urinary metabolism of dextromethorphan in man," Arzneim.-Forsch./Drug Research 37:1304-1306 (1987).
Guttendorf, R. J., et al, "Simplified phenotyping with dextromethorphan by thin-layer chromatography," Ther. Drug. Monit. 10:490-498 (1988).
Kupfer, A., et al, "Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism," Lancet: 517-518 (Sep. 1, 1984).
Physician's Desk Reference, 44th Edition (1990), pp. 670-671 (Medical Economics Company, 1990).
Inaba, T., et al, "In vitro inhibition studies of two isozymes of human liver cytochrome P-450," Drug Metabolism and Diposition 13: 443-447 (1985).
Inbaba, T., et al, "Quinidine: Potent inhibition of sparteine and debrisoquin oxidation in vivo," Br. J. Clin. Pharmacol. 22: 199-200 (1986).
Broly, F., et al, "Effect of quinidine on the dextromethorphan O-methylase activity of microsomal fractions from human liver," Br. J. Clin. Pharmacol. 28: 29-36 (1989).
Broly, F., et al., "Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes," Biochem. Pharmacol. 39: 1045-1053 (1990).
Brinn, R., et al, "Sparteine oxidation is practically abolished in quinidine-treated patients," Br. J. Clin. Pharmacol. 22: 194-197 (1986).
Brosen, K., et al, "Extensive metabolizers of debrisoquin become poor metabolizers during quinidine treatment," Pharmacol. Toxicol. 60: 312-314 (1987).
Nielsen, M. D., et al, "A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man," Br. J. Clin. Pharmacol. 29: 299-304 (1990).
Walker, E. O., and Hunt, V. P., "An open label trial of dextromethorphan in Huntington's Disease," Clin. Neuropharmacol. 12: 322-330 (1989).
Albers, G. W., et al, "Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia," Stroke 22: 1075-1077 (1991).
Applebaum, J. S., et al, "Dextromethorphan in the treatment of ALS: A Pilot Study," Abstract number 960S (p. 393) in Neurology 41 (Suppl. 1), Mar. 1991.
Kelly Patrick D.
Raymond Richard L.
LandOfFree
Use of dextromethorphan and an oxidase inhibitor to treat dermat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of dextromethorphan and an oxidase inhibitor to treat dermat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of dextromethorphan and an oxidase inhibitor to treat dermat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1991640